Discovery of Isojacareubin as a covalent inhibitor of SARS‐CoV‐2 main protease using structural and experimental approaches
A Khan, W Heng, K Imran, G Zhu, J Ji… - Journal of Medical …, 2023 - Wiley Online Library
The ongoing pandemic with the emergence of immune evasion potential and, particularly,
the current omicron subvariants intensified the situation further. Although vaccines are …
the current omicron subvariants intensified the situation further. Although vaccines are …
Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches.
A Khan, K Imran, G Zhu, J Ji, Y Zhang… - Journal of Medical …, 2023 - europepmc.org
The ongoing pandemic with the emergence of immune evasion potential and particularly the
current omicron sub variants intensified the situation further. Although vaccine are available …
current omicron sub variants intensified the situation further. Although vaccine are available …
Discovery of Isojacareubin as a covalent inhibitor of SARS‐CoV‐2 main protease using structural and experimental approaches.
A Khan, W Heng, K Imran, G Zhu, J Ji… - Journal of Medical …, 2023 - search.ebscohost.com
The ongoing pandemic with the emergence of immune evasion potential and, particularly,
the current omicron subvariants intensified the situation further. Although vaccines are …
the current omicron subvariants intensified the situation further. Although vaccines are …
Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches
A Khan, W Heng, K Imran, G Zhu, J Ji… - Journal of medical …, 2023 - pubmed.ncbi.nlm.nih.gov
The ongoing pandemic with the emergence of immune evasion potential and, particularly,
the current omicron subvariants intensified the situation further. Although vaccines are …
the current omicron subvariants intensified the situation further. Although vaccines are …